Windlas Biotech Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Windlas Biotech Limited Reports its Q1 and FY26 Financial Results.".
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported its Q1FY26 results, marking the 10th consecutive quarter of record revenue. Consolidated revenue grew 19.9% YoY to Rs. 210.1 crores, driven by strong performance across all three business verticals. EBITDA rose 27% YoY to Rs. 26.5 crores with margin expansion of 70 bps to 12.6%, while PAT jumped 31.1% YoY to Rs. 17.7 crores. EPS stood at Rs. 8.4, up 30% YoY. The CDMO vertical led with Rs. 160.2 crores (76% of revenue, up 18%), Trade Generics grew 25% to Rs. 43.9 crores, and Exports surged 45% to Rs. 6.0 crores. The company also paid a dividend of Rs. 5.8 per share (Rs. 12.2 crores total) for FY25 in August 2025.
Broadly positive for shareholders – consistent double-digit growth in revenue, profitability, and margins signals strong business momentum. The export vertical's 45% growth and ongoing Plant 6 capacity expansion hint at future revenue upside, while the dividend payout reflects healthy cash generation.